Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 39kWORD 19k
19 March 2019
E-001419-19
Question for written answer E-001419-19
to the Commission
Rule 130
Elisabetta Gardini (PPE)

 Subject:  Joint Action on Rare Cancers (JARC)
 Answer in writing 

Although the EU’s Cross-Border Healthcare Directive was well received when it came into force in 2011, the European Reference Networks (ERNs) launched in 2017 are now in jeopardy.

While Parliament’s recent report on the implementation of the directive is clearly important, it failed to mention the Joint Action on Rare Cancers (JARC) that is due to end in October 2019 and the group’s soon-to-be-published recommendations for optimising the development of ERNs for rare cancers. It is important that the Commission has mechanisms in place to enable it to deliver the JARC’s recommendations. In this context:
1. Can the Commission clarify what mechanisms it will put in place to ensure that the JARC’s recommendations on the development of ERNs are implemented by Member States and what steps it will take to guarantee that the JARC can continue its efforts after October 2019?
2. Is the Commission planning to develop, in collaboration with the JARC’s partners, a plan for interaction between national healthcare networks for rare cancers and ERNs for rare cancers?
3. Will it also provide further guidance to Member States on developing reimbursement procedures for rare cancer patients in accordance with the Cross-Border Healthcare Directive and making the most of ERNs?
Last updated: 3 April 2019Legal notice